5-AMINOSALICYLATE AND CHRONIC INFLAMMATORY BOWEL-DISEASE IN CHILDREN

被引：2
|
作者：
KLOTZ, U
机构：
来源：
KLINISCHE PADIATRIE | 1995年 / 207卷 / 05期
关键词：
D O I：
10.1055/s-2008-1046553
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
5-Aminosalicylate (mesalazine; 5-AS) represents a new therapeutic strategy in chronic inflammatory bowel disease. The drug (active metabolite of sulfasalazine) has proven its clinical efficacy and safety in numerous controlled studies in adults. However only limited data are available for the pediatric population. This brief review summarises the published spares information on this promising agent. As pharmacokinetic properties of 5-AS are age-independent and since 5-AS has a wide margin of safety clinical studies and use of this drug should be encouraged also in children.
引用
收藏
页码：285 / 287
页数：3
相关论文
共 50 条
  • [1] 5-Aminosalicylate (5-ASA) Induced Nephrotoxicity in Inflammatory Bowel Disease
    So, Kenji
    Bewshea, Claire M.
    Heap, Graham A.
    Muller, Andrew F.
    Delaney, Michael P.
    Daneshmend, Tawfique K.
    Hart, Ailsa L.
    Orchard, Timothy R.
    Irving, Peter M.
    D'Souza, Richard
    Mulgrew, Chris
    Kwan, Jonathan
    Silverberg, Mark S.
    Gearry, Richard B.
    Radford-Smith, Graham
    Watermeyer, Gillian
    D'Inca, Renata
    Annese, Vito
    Tsianos, Epameinondas V.
    Russell, Richard K.
    Wilson, David C.
    Parkes, Miles
    Satsangi, Jack
    Oram, Richard A.
    Weersma, Rinse K.
    Lawrance, Ian C.
    Holden, Arthur L.
    Lees, Charlie W.
    Ahmad, Tariq
    GASTROENTEROLOGY, 2013, 144 (05) : S112 - S112
  • [2] 5-AMINOSALICYLATE (5-ASA) INDUCED NEPHROTOXICITY IN INFLAMMATORY BOWEL DISEASE
    So, K.
    Bewshea, C.
    Heap, G. A.
    Muller, A. F.
    Daneshmend, T. K.
    Hart, A. L.
    Orchard, T. R.
    Irving, P. M.
    Russell, R. K.
    Wilson, D. C.
    Parkes, M.
    Satsangi, J.
    Lees, C. W.
    Ahmad, T.
    GUT, 2013, 62 : A22 - A22
  • [3] Indications for 5-aminosalicylate in inflammatory bowel disease:Is the body of evidence complete?
    Ad A van Bodegraven
    Chris JJ Mulder
    World Journal of Gastroenterology, 2006, (38) : 6115 - 6123
  • [4] Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia
    Selinger, Christian P.
    Kemp, Andrew
    Leong, Rupert W. L.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (03) : 329 - 334
  • [5] Indications for 5-aminosalicylate in inflammatory bowel disease: Is the body of evidence complete?
    van Bodegraven, Ad A.
    Mulder, Chris J. J.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (38) : 6115 - 6123
  • [6] Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review
    van de Meeberg, Maartje M.
    Schultheiss, Johannes P. D.
    Oldenburg, Bas
    Fidder, Herma H.
    Huitema, Alwin D. R.
    DIGESTION, 2020, 101 (03) : 245 - 261
  • [7] CHRONIC INFLAMMATORY BOWEL-DISEASE IN CHILDREN
    DOUGLAS, JR
    CAMPBELL, CA
    WALKERSMITH, JA
    WILLIAMS, CB
    AUSTRALIAN PAEDIATRIC JOURNAL, 1981, 17 (02): : 144 - 144
  • [8] 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study
    van Staa, TP
    Card, T
    Logan, RF
    Leufkens, HGM
    GUT, 2005, 54 (11) : 1573 - 1578
  • [9] PATHOLOGY OF CHRONIC INFLAMMATORY BOWEL-DISEASE IN CHILDREN
    DOMIZIO, P
    BAILLIERES CLINICAL GASTROENTEROLOGY, 1994, 8 (01): : 35 - 63
  • [10] CONCOMITANT 5-AMINOSALICYLATE USE IN INFLAMMATORY BOWEL DISEASE PATIENTS ON BIOLOGIC THERAPY: A PRELIMINARY COST ANALYSIS
    Leow, Khai
    Gukathasan, Ramanan
    Bates, Madeleine
    Alfred, Sarah
    Danahay, Alison
    Chhaya, Vivek
    GUT, 2021, 70 : A96 - A96
12345